Quantifying the Clinical Benefit of Magnetic Resonance Imaging (MRI) in Lung Cancer Radiotherapy

Quantifying the Clinical Benefit of MRI in Lung Cancer Radiotherapy

Status

Terminated

Phases

Early Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12616001075471

Acronym

Nil

Enrollment

Registered

2016-08-10

Start date

2013-10-29

Completion date

2018-05-25

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to quantify clinical benefit of Magnetic resonance imaging (MRI) during lung cancer radiotherapy. Who is it for? Participants aged 18 years or over and have histological or cytological confirmed lung cancer scheduled to be treated with 12 or more fractions of treatment. Study details: All participants in this study will undergo MRI scans in addition to standard scans used during radiotherapy treatment (CT and PET). Participant of this trial will undergo a total of six MRI scans which will be performed before radiotherapy treatment starts, and at treatment day 1, day 11 and day 21 (where applicable), and three and six months post treatment completion. MRI scans acquired will not alter or impact participant’s treatment intent.This study will not impact on the participants standard treatment.

Interventions

There is no direct intervention to patients standard treatment. During the course radiotherapy, participants will receive MRI scans at specified time points to identify changes during the course of treatment, A total of 6 MRI scans to be performed. Scan 1 is performed at least 1 week prior to the start of treatment. Scan 2 is performed on Day 1 of treatment. Subsequent scans are performed on day 11 and 21 during treatment. Follow up MRI scans at 3months and 6 months post treatment. Participants PET and CT scans acquired as part standard radiotherapy planning will be utilised as well. MRI images acquired for this study will not impact of change treatment intent for participants. All images will be utilised retrospectively.

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1) Histological or cytological confirmed lung cancer 3) Patient has good renal function ( GFR < 53ml/min) 4) Patient is receiving 12 or more fractions of treatment

Exclusion criteria

Contraindication to MRI Prior surgery to area of treatment

Outcome results